tradingkey.logo

Rapid Micro Biosystems Inc

RPID
查看详细走势图
3.870USD
+0.190+5.16%
收盘 02/06, 16:00美东报价延迟15分钟
171.48M总市值
亏损市盈率 TTM

Rapid Micro Biosystems Inc

3.870
+0.190+5.16%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+5.16%

5天

-12.64%

1月

+14.50%

6月

+13.49%

今年开始到现在

+33.45%

1年

+24.84%

查看详细走势图

TradingKey Rapid Micro Biosystems Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Rapid Micro Biosystems Inc当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理,在医疗设备与耗材行业排名98/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价8.00。中期看,股价处于上升通道。近一个月,市场表现很强,技术面评分较高,但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Rapid Micro Biosystems Inc评分

相关信息

行业排名
98 / 205
全市场排名
261 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Rapid Micro Biosystems Inc亮点

亮点风险
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
业绩高增长
公司营业收入稳步增长,连续3年增长63.72%
业绩增长期
公司处于发展阶段,最新年度总收入28.05M美元
估值低估
公司最新PE估值-3.88,处于3年历史低位
机构减仓
最新机构持股23.36M股,环比减少7.42%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值978.78K

分析师目标

根据 4 位分析师
买入
评级
8.000
目标均价
+117.39%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Rapid Micro Biosystems Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Rapid Micro Biosystems Inc简介

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
公司代码RPID
公司Rapid Micro Biosystems Inc
CEOSpignesi (Robert)
网址https://www.rapidmicrobio.com/
KeyAI